Rezigene

Broad-spectrum therapies for neurodegeneration designed to combat proteotoxicity in FTD, ALS, and more by restoring healthy cellular protein quality control

  • Stage Prototype Ready
  • Industry Biotechnology
  • Location Baltimore, MD, USA
  • Currency USD
  • Founded May 2023
  • Employees 3
  • Incorporation Type LLC
  • Website Stealth

Company Summary

REZIGENE is combating proteotoxicity-driven diseases such as ALS, FTD, and more. Pioneered by Dr. Jiou Wang at Johns Hopkins, who's discovery of a novel biological target has enabled the development of small molecule inhibitors to treat toxic misfolded proteins. Our leading product, FX8, diminishes protein toxicity and bolsters motor neuron health, promising enhanced patient outcomes.

Team

  • Bawer Miran
    Strategic Advisor Business Development

    14 Years Operations and Business Development experience in manufacturing and clinical trials.

  • Daniel Saragnese
    Co-founder, Strategic Advisor

    Led CMC at venture-backed biotech spin-outs of Stanford and Johns Hopkins

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free